

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) June 28, 2013**

---

**BECTON, DICKINSON AND COMPANY**

**(Exact Name of Registrant as Specified in Its Charter)**

---

**New Jersey**  
**(State or Other Jurisdiction of Incorporation)**

**001-4802**  
**(Commission File Number)**

**22-0760120**  
**(IRS Employer Identification No.)**

**1 Becton Drive, Franklin Lakes, New Jersey**  
**(Address of Principal Executive Offices)**

**07417-1880**  
**(Zip Code)**

**(201) 847-6800**  
**(Registrant's Telephone Number, Including Area Code)**

**N/A**  
**(Former Name or Former Address, if Changed Since Last Report)**

---

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On June 28, 2013, Becton, Dickinson and Company (“BD”) elected Christopher R. Reidy, 55, as Chief Financial Officer and Executive Vice President of Administration, effective July 15, 2013, succeeding Suketu Upadhyay, who has served as BD’s interim Chief Financial Officer since November 2012. Mr. Reidy previously served as Vice President and Chief Financial Officer of ADP Corporation from 2006 to 2012. Effective July 15, 2013, Mr. Upadhyay will have expanded responsibilities across BD’s finance organization and will assume the title of Senior Vice President, Finance. He will continue to serve as BD’s principal accounting officer.

Mr. Reidy will receive a base salary of \$675,000, and his target annual incentive award under BD’s Performance Incentive Plan will be 85% of salary, which will be pro-rated for fiscal year 2013. Mr. Reidy will also receive an equity compensation award in fiscal year 2014 with a grant date value of \$2 million. Mr. Reidy and BD will also enter into an agreement providing for his continued employment for a period of two years following a change of control of BD, with a severance multiple of two times salary and bonus, similar to agreements with other executive officers that have been previously disclosed.

A copy of the press release issued by BD in connection with this election is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

Exhibit 99.1 Press release dated July 8, 2013, which is furnished pursuant to Item 5.02.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: /s/ Gary DeFazio  
Gary DeFazio  
Vice President and Corporate Secretary

Date: July 8, 2013

99.1 Press release dated July 8, 2013, furnished pursuant to Item 5.02

1 Becton Drive  
Franklin Lakes, NJ 07417  
www.bd.com

## News Release



### Contact:

Monique N. Dolecki, Investor Relations – 201-847-5453  
Colleen T. White, Corporate Communications – 201-847-5369

### **BD Appoints Christopher Reidy as Chief Financial Officer**

**Franklin Lakes, NJ (July 8, 2013)**– BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global technology company, today announced the appointment of Christopher Reidy as Chief Financial Officer and Executive Vice President of Administration, effective July 15, 2013. Mr. Reidy will report to Vincent A. Forlenza, Chairman, Chief Executive Officer and President.

Mr. Reidy, 55, will be responsible for executive management and oversight of BD's global financial operations and shared services, as well as oversight of Information Technology after a transition period. He joins BD from ADP Corporation, where he served as Corporate Vice President and CFO for six years. Prior to ADP, Mr. Reidy's more than 30 years of experience includes serving as CFO at NBA Properties, Inc.; Vice President, Controller & Chief Accounting Officer and division CFO roles at AT&T Corporation; and Audit Partner at Deloitte & Touche.

"It is a pleasure to welcome Chris to our executive management team," said Mr. Forlenza. "He possesses significant financial and operational expertise, complemented by strategic and execution skills. He is well positioned to help drive BD's strategy of accelerating growth through innovation, geographic expansion and operating effectiveness to create value for our customers and shareholders."

Mr. Reidy, a Certified Public Accountant, earned his MBA from Harvard University and his B.S. in accounting from St. Francis College.

Suketu ("Suky") Upadhyay, who has been serving as Acting Chief Financial Officer since November 2012, will have expanded responsibilities across BD's finance organization and will serve as the Company's principal accounting officer in his new role as Senior Vice President, Finance, also effective July 15, 2013.

### About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit [www.bd.com](http://www.bd.com).

\*\*\*